Needham & Company Maintains a 'Buy' on Hi Tech Pharmacal (HITK); Positive Sense of Déjà Vu as Generic Flonase Drives 1QFY12 Results
Tweet Send to a Friend
Needham & Company maintains a 'Buy' on Hi Tech Pharmacal (NASDAQ: HITK) price target of $36.00.
Needham analyst says, "HITK ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "HITK ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
